Takeda Pharmaceuticals Archives - Medical Design Sourcing

Takeda wins approval for eosinophilic esophagitis drug Eohilia

Takeda announced this week that it received FDA approval for its Eohilia (budesonide oral suspension) therapy.

This makes Eohilia the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). Takeda plans to offer it in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

Eohilia, a corticosteroid, is indicated for 12 weeks of treatment in patients 11 years and older with EoE. Developed specifically for EoE, the novel formulation of budesonide confers thixotropic properties, according to a news release. This allows for more free flow when shaken, returning to a more viscous state when swallowed.

Takeda picked up approval on the back of efficacy and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week studies.

“For most of us, eating is a simple experience. But for people living with eosinophilic esophagitis, sitting down for a meal…

Report: Pharma kicks off year with drug price hikes

Image from https://torange.biz/medications-big-money-19928

Reuters reports that a number of big-name drugmakers, including Pfizer, Sanofi and Takeda plan to raise drug prices to start the year.

According to the report, the price hikes apply to more than 500 drugs. Excluding different doses and formulations, the reach extends to more than 140 brands of drugs. Reuters said healthcare research firm 3 Axis Advisors analyzed data that uncovered these increases.

This move comes just weeks after the Biden Administration signaled its intent to target the pricing of dozens of prescription drugs. The Administration announced a strategy under the Inflation Reduction Act to focus on 48 Medicare Part B drugs that have raise…

MedTech 100 roundup: Industry rebounds from massive dip

The medtech industry saw its largest fall in several months last week, but it has rebounded slightly after a couple of bad weeks.

A strong start to 2021 hit a skid at the end of February and carried over into March, with MassDevice‘s MedTech 100 index hitting its lowest point on March 8 (102.16). It had only notched an all-time best of 110.96 on Feb. 15, leading to a precipitous fall not seen since October.

While the heights of last month have not yet been returned to, the industry has shown signs of bouncing back. The index ended the week (March 12) at 104.62, marking a 1.3% rise from the 103.3-point mark set one week before (March 5).

The industry remains in a strong position and one that is particularly stronger than it was at this time a year ago, as the index is now 13.3% up on the pre-COVID-19 pandemic high of 92.32 set on Feb. 19, 2020.

Nearly one year ago, on March 23, 2020, as the pandemic took hold, the industry sat at 62.13 points on th…

Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M

Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million.

Osaka, Japan-based Takeda exercised its option to acquire Maverick and in doing so will obtain its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages.

Get the full story at our sister site, Drug Delivery Business News.

Evox Therapeutics completes $95.4M Series C

Evox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round.

Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass., to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company NuVasive (NSDQ:NUVA) and diagnostic company Life Technologies, said management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost mono…

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tools supplier that its Executive Chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass. to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza had acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company Nuvasive and diagnostic leader Life Technologies, says management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost monopolistic …